BIVI · Biovie Inc.
$2.40
+0.24 (+10.88%)
At close · Aug 31
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These circumstances raise substantial doubt on the Company's ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.”View the 10-K filed Aug 13, 2026
Market Cap
$16.29M
Shares
7.54M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$22.07M
-25.8%
FY2026
Diluted EPS
-$3.05
+74.8%
FY2026
Operating Cash Flow
-$19.02M
0%
FY2026
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $13.96M | $9.27M | $23.1M | $33.3M | $17.26M | $2.54M | $1.15M | $1.01M | $370.85K | $466.35K | $37.9K | $4196 | $49.42K | — | |
| — | $8.51M | $8.57M | — | — | — | — | — | — | — | — | — | — | — | — | |
| $8.79M | — | $8.57M | $8.85M | $11.55M | $9.77M | $4.64M | $1.31M | $1.26M | $1.77M | $69.12K | $15.32K | $16.47K | $25.89K | $17.52K | |
| — | $178.34K | $229.38K | $229.38K | $229.38K | $229.38K | $229.38K | $229.38K | $229.38K | $229.38K | $229.38K | $51.04K | — | — | — | |
| — | $22.65M | $18.07M | $32.18M | $45.08M | $27.25M | $138.05M | $2.69M | $2.5M | $2.37M | $1.55M | $432.03K | $233.38K | $322.39K | $17.52K | |
| — | -$22.65M | -$18.07M | -$32.18M | -$45.08M | -$27.25M | -$138.05M | -$2.69M | -$2.5M | -$2.37M | -$1.55M | -$432.03K | -$233.38K | — | — | |
| — | $17.9K | $332.72K | $2.89M | $4.3M | $2.16M | $559.46K | $4.77M | $273 | $40.96K | — | $81 | — | — | — | |
| — | $578.87K | $524.08K | $59.05K | -$5.18M | — | — | — | — | — | — | — | — | — | — | |
| — | -$22.07M | -$17.54M | -$32.12M | -$50.26M | -$26.08M | -$130.25M | -$16.68M | -$2.44M | -$2.43M | -$1.33M | -$431.92K | -$233.01K | -$321.9K | -$17.51K | |
| — | — | — | -$33.01M | -$50.26M | -$26.08M | — | — | — | — | — | — | — | — | — | |
| — | — | -$17.91M | -$33.18M | -$50.08M | -$26.08M | — | — | — | — | — | — | — | — | — | |
| USD/shares | — | -$3.05 | -$12.12 | -$73.05 | -$154.70 | -$106.00 | -$1,482.00 | -$685.00 | -$98.00 | — | — | — | — | — | — |
| USD/shares | — | -$3.05 | -$12.12 | -$73.05 | -$154.70 | -$106.00 | -$1,482.00 | -$685.00 | -$98.00 | — | — | — | — | — | — |
| shares | — | 7.25M | 1.48M | 451.85K | 324.83K | 246.63K | 124.03K | 49.29K | 25.4K | 957.58K | 893.91K | 871.99K | 872.1K | 870.84K | 412.26K |
| shares | — | 7.25M | 1.48M | 451.85K | 324.83K | 246.63K | 124.03K | 49.29K | 25.4K | 957.58K | 893.91K | 871.99K | 872.1K | 870.84K | 412.26K |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.70×
EV/EBIT
—
P/E (TTM)
—
Peer median 2.89×
Peer medians compare against the 220 similar-size Biotechnology companies (of 508 listed).
Key facts
CIK
1580149
CUSIP
09074F504
13F (30d)
38 filings
36 filers
Visit website
Investor relations